Advisors Asset Management Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 179,004 shares of the medical research company's stock, valued at approximately $75,452,000. Amgen accounts for approximately 0.7% of Advisors Asset Management Inc.'s holdings, making the stock its 24th largest position.
A number of other institutional investors have also modified their holdings of the stock. Wellington Altus USA Inc. increased its stake in shares of Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock valued at $28,000 after buying an additional 34 shares during the period. Quest 10 Wealth Builders Inc. raised its holdings in shares of Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company's stock valued at $34,000 after acquiring an additional 55 shares in the last quarter. Nvwm LLC lifted its stake in Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company's stock worth $35,000 after acquiring an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new stake in Amgen in the second quarter worth about $36,000. Finally, PFS Partners LLC lifted its stake in Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company's stock worth $36,000 after acquiring an additional 42 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.
Amgen Trading Down 1.1%
Amgen stock opened at $438.82 on Friday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The stock has a market cap of $237.36 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. The stock has a 50-day moving average of $429.28 and a two-hundred day moving average of $383.32. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts' consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company's revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.64 earnings per share. On average, research analysts anticipate that Amgen Inc. will post 23.37 EPS for the current fiscal year.
Amgen Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen's dividend payout ratio is presently 58.47%.
Analysts Set New Price Targets
Several research analysts have issued reports on AMGN shares. HSBC cut shares of Amgen from a "buy" rating to a "hold" rating and dropped their target price for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a report on Sunday, October 18th. JPMorgan Chase & Co. upped their price target on shares of Amgen from $350.00 to $425.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Weiss Ratings upgraded shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. Finally, Barclays increased their price objective on shares of Amgen from $400.00 to $430.00 and gave the company an "equal weight" rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $428.62.
View Our Latest Research Report on Amgen
Amgen Profile
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.